For HER2 subtype, [34] confirms that agents targeting GAB2 or GAB2-dependent pathways may be useful for treating breast tumors that overexpress HER2, and thus we include GAB2 as a correlated gene for HER2 type breast cancer. Here, ERBB2 is linked to breast neoplasm.